Log in

Multiple sclerosis: Sanofi joins forces with American biotech

Sanofi and US biotech Principia announced Thursday an agreement, worth up to 765 million, to develop a treatment for multiple sclerosis.

The agreement concerns the drug PRN2246 developed by Principia and whose French laboratory will take care of the future stages of development. In exchange, Sanofi will benefit from an "exclusive worldwide license" to market it.

"External collaborations such as these complement our in-house research and development expertise and could help to scale up the development of new treatments for patients with these serious diseases," said Rita Balice-Gordon, head of health and nutrition. therapeutic research in neuroscience at Sanofi.

The French laboratory will make a first payment of 40 millions of dollars (34,46 million) to biotech, then other payments that could eventually reach a total of 765 million.

Principia, for its part, will receive royalties on sales of the product and may, if it so wishes, co-finance the Phase III development in exchange for either higher royalties or a profit-sharing agreement with the Member States. -United.

When administered orally, PRN2246 has the advantage of being able to access the brain and the spinal cord, thus acting on the signaling of immune and cerebral cells. Both companies view this treatment as a "promising potential" for multiple sclerosis and other diseases of the central nervous system.

The statement said the deal is yet to be finalized, likely in the fourth quarter, "subject to normal regulatory approvals".

a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )

  group    administrators A3P
& Project Managers

letter   newsletter A3P